| Product Unit Size | Cost | Quantity | Stock |
|---|
CCT-196969 pan-Raf inhibitor that also exhibits anti-SRC activity. It shows efficacy in melanoma and colorectal cancer cell lines with B-Raf mutations, and is a potential treatment for patients who develop resistance to first-line B-Raf and MEK inhibitors.
| Cas No. | 1163719-56-9 |
|---|---|
| Purity | ≥98% |
| Formula | C27H24FN7O3 |
| Formula Wt. | 513.53 |
| IUPAC Name | 1-{2-Fluoro-4-[(3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy]phenyl}-3-[3-(2-methyl-2-propanyl)-1-phenyl-1H-pyrazol-5-yl]urea |
| Synonym | CCT 196969, CCT196969 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Girotti M., Lopes F., et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell. 27(1):85-96 (2015). PMID: 25500121.
